Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"COOPER PHARMA","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$20.3 million","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical's Fexuprazan Takes its First Step into Africa Entering into a Partnership with Cooper Pharma, the No. 1 Pharmaceutical Company in Morocco in the Field of Digestive Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"MOROCCO","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Cooper Lab

    Menu

    Cooper Lab

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              COOPER PHARMA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Morocco
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Daewoong Pharmaceutical's Fexuprazan Takes its First Step into Africa Entering into a Partnership with Cooper Pharma, the No. 1 Pharmaceutical Company in Morocco in the Fie...

              Details:

              Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).

              Lead Product(s): Fexuprazan

              Therapeutic Area: Gastroenterology Product Name: Fexuclue

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Daewoong Pharmaceutical

              Deal Size: $20.3 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY